Richard Larouche, MD

Director, Medical Affairs
PharmaNet/i3
Papers:
OR17-2 ISIS-GCCRRX, a Novel Glucocorticoid (GC) Receptor Antisense Drug Reduces Cholesterol and Triglycerides and Attenuates Dexamethasone Induced Hepatic Insulin Resistance without Systemic GC Antagonism in Normal Subjects